Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.33), $0.13 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $6.77 million versus the consensus estimate of $1.33 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.